

**LSCMMG New Drug Requests Work Plan
2022/23 Financial Year
December 2022**

Medicines	Indication	Further Information
New Medicine Reviews for January LSCMMG meeting		
Degaralix	treatment of adult male patients with advanced hormone-dependent prostate cancer - patients without spinal metastases	Request by ELCCG
Oritavancin	Management of patients with skin and soft tissue infections	Request by ELMMB
Medicines prioritised for New Medicine Reviews - for future LSCMMG meeting		
Tolvaptan	SIADH in patients not requiring chemotherapy	Requested by BTHT. Gap in commissioning position identified - other indications NHSE.
Estradiol / micronised progesterone (Bijuve)	Continuous combined hormone replacement therapy (HRT) for estrogen deficiency symptoms in postmenopausal women with intact uterus and with at least 12 months since last menses	Horizon Scanning (SMC). Public interest expected to be high due to recent media coverage of HRT/menopause.
Nephrotrans (gastro-resistant sodium bicarbonate)	Treatment of metabolic acidosis in chronic kidney disease	Request from Lancashire Teaching Hospitals Trust, renal. Potentially better tolerated and more effective than current treatments.
Ogluo pre-filled glucagon pen	Treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.	Request from Fylde Coast ICB region. New presentation of established drug. Could potentially have cost impact as more expensive than currently used product.
Iqoro device	Treatment of Acid Reflux and Dysphagia	Request from Central Lancashire ICB region. Low level of requests but true potential for use unknown.
Therabite	To restore mobility after trismus and mandibular hypomobility	Request from Fylde Coast ICB region. Could be very low use, request from clinician.
Trifarotene	For the cutaneous treatment of acne vulgaris of the face and/or the trunk in patients from 12 years of age and older, when many comedones, papules and pustules are present	Horizon scanning (SMC). No requests.
Infliximab increased dosing	Treatment of ulcerative colitis and Crohn's disease	Requested by ELHT. Awaiting pathway discussions before proceeding.